Can Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa

AIDS and Behavior

Volumn 20, Issue 11, 2016, Pages 2717-2728

  Evans, Denise ^a   Berhanu, Rebecca ^b   Moyo, Faith ^a   Nguweneza, Arthemon ^a   Long, Lawrence ^a   Fox, Matthew P ^a,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b RIGHT TO CARE   (South Africa)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adherence; Electronic adherence monitoring device (EAMD); Second line; Viral suppression; Wisepill

Indexed keywords

ADULT; CELL CULTURE MONITORING; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COUNSELING; HUMAN; HUMAN EXPERIMENT; HUMAN VERSUS ANIMAL COMPARISON; PILOT STUDY; POSTMARKETING SURVEILLANCE; RISK FACTOR; SOUTH AFRICA; VIRUS LOAD; COMBINATION DRUG THERAPY; DEVICES; DRUG EFFECTS; DRUG MONITORING; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT EDUCATION; RETREATMENT; STATISTICS AND NUMERICAL DATA; TEXT MESSAGING; TREATMENT FAILURE; VIROLOGY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PILOT PROJECTS; RETREATMENT; SOUTH AFRICA; TEXT MESSAGING; TREATMENT FAILURE; VIRAL LOAD;

EID: 84965057589     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-016-1417-7     Document Type: Article

References (38)

1. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010;85(1):1.
2. Mutevedzi PC, Newell ML. The changing face of the HIV epidemic in sub-Saharan Africa. Trop Med Int Health. 2014;19(9):1015–28. doi:10.1111/tmi.12344.
3. Bor J, Herbst K, Newell ML, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339:961–5.
4. Court R, Leisegang R, Stewart A, Sunpath H, Murphy R, Winternheimer P, Ally M, Maartens G. Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study. BMC Infect Dis. 2014;14:664.
5. McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013;91(5):377.
6. Viswanathan S, Detels R, Mehta SH, Macatangay BJ, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601–11.
7. Chkhartishvili N, Sharvadze L, Dvali N, Karchava M, Rukhadze N, Lomtadze M, Chokoshvili O, Tsertsvadze T. Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia. AIDS Res Ther. 2014;11:18.
8. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Nagalingeswaran N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
9. Machtinger EL, Bangsberg DR. Adherence and HIV/AIDS: adherence to HIV antiretroviral therapy. HRSA Care Action, US Department of Health and Human Services. 2006; pp.1–30.
10. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53(4):500–6.
11. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010;24(6):915–9.
12. Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, Wood R, Hernán MA, Sterne JA, Egger M, Boulle A. IeDEA-SA collaboration. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr. 2012;60(4):428–37.
13. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26(8):929–38.
14. Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Bärnighausen T. Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS. 2014;28(Suppl 2):S187–S204.
15. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis. 2011;12:942–51.
16. Gill CJ, Sabin LL, Hamer DH, Keyi X, Jianbo Z, Li T, Wu WJ, Wilson IB, Desilva MB. Importance of dose timing to achieving undetectable viral loads. AIDS Behav. 2010;14(4):785–93.
17. Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, Bangsberg DR. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.
18. Sabin LL, Bachman DeSilva M, Gill CJ, Zhong L, Vian T, Wubin X, Cheng F, Xu K, Lan G, Haberer JE, Bangsberg DR, Li Y, Lu H, Gifford AL. Improving adherence to antiretroviral therapy with triggered real-time text message reminders: the China Adherence Through Technology Study. J Acquir Immune Defic Syndr. 2015;69(5):551–9.
19. Orrell C, Cohen K, Mauff K, Bangsberg DR, Maartens G, Wood R. A randomized controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy. JAIDS. 2015;70(5):495–502.
20. Fox MP, Maskew M, MacPhail P, Long L, Brennan A, Westreich D, et al. Cohort profile: the Themba Lethu Clinical HIV Cohort, Johannesburg, South Africa. Int J Epidemiol. 2012;42(2):430–9.
21. Department of Health, Republic of South Africa. The South African Antiretroviral treatment guidelines; 2010 (Internet). (cited 2014 Jan 17). http://www.uj.ac.za/EN/CorporateServices/ioha/Documentation/Documents/ART20Guideline.pdf
22. Department of Health, Republic if South Africa. The South African antiretroviral treatment guidelines; 2013 (Internet). (cited 2014 Jan 17). http://www.kznhealth.gov.za/medicine/2013_ART_Gudelines.pdf
23. National Department of Health, Republic of South Africa. National consolidated guidelines for the prevention of mother to child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults; 2015 http://www.sahivsoc.org/upload/documents/ART%20Guidelines%2015052015.pdf. Accessed 28 July 2015.
24. Shearer K, Maskew M, Ajayi T, Berhanu R, Majuba P, Sanne I, Fox MP. Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014;23:56–62.
25. Fox MP, Brennan A, Maskew M, MacPhail P, Sanne I. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010;15:405–13.
26. Kleiman S. Phenomenology: to wonder and search for meanings. Nurse Res. 2004;11(4):7–19.
27. Wallis CL, Papathanasopolous MA, Fox M, Conradie F, Ive P, Orrell C, Zeinecker J, Sanne I, Wood R, McIntyre J, Stevens W. CIPRA-SA project 1 study team. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012;17(2):313–20.
28. Cox et al. Addressing treatment failure amongst adults on second-line antiretroviral therapy in Khayelitsha. 7th South African AIDS conference, June 2015, Durban South Africa.
29. Garone DB, Conradie K, Patten G, Cornell M, Goemaere E, Kunene J, Kerschberger B, Ford N, Boulle A, van Cutsem G. High rate of virological re-suppression among patients failing second-line antiretroviral therapy following enhanced adherence support: a model of care in Khayelitsha, South Africa. South Afr J HIV Med. 2013;14(4):170–6.
30. Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014;209(5):711–20.
31. Wasti S, Simkhada P, Randall J, Freeman JV, van Teijlingen E. Factors influencing adherence to antiretroviral treatment in Nepal: a Mixed-Methods Study. PLoS One. 2012;7(5):e35547.
32. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-Infected patients receiving Lopinavir/Ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. JAIDS J Acquir Immune Defic Syndr. 2007;45(1):4–8.
33. Genberg BL, Lee Y, Rogers WH, Wilson IB. Four types of barriers to adherence of antiretroviral therapy are associated with decreased adherence over time. AIDS Behav. 2015;19(1):85–92.
34. Morojele NK, Kekwaletswe CT, Nkosi S. Associations between alcohol use other psychosocial factors, structural factors and antiretroviral therapy (ART) adherence among South African ART recipients. AIDS Behav. 2014;18(3):519–24.
35. van Loggerenberg F, Gray D, Gengiah S, Kunene P, Gengiah TN, Naidoo K, Grant AD. A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa. AIDS Patient Care STDS. 2015;29(5):299–306.
36. Haberer J, Muzoora C, Hunt P, Martin J, Siedner M, Bangsberg D. Real-time HIV ART adherence monitoring predicts loss of viral suppression and subsequent resuppression: rural Uganda. In: 20th Conference on retroviruses and other opportunistic infections (CROI). Atlanta, 2013. http://www.retroconference.org/2013b/Abstracts/46632.htm. Accessed 9 May 2013.
37. Wise J, Operario D. Use of electronic reminder devices to improve adherence to antiretroviral therapy: a systematic review. AIDS Patient Care STDs. 2008;22:495–504.
38. Murphy RA, Sunpath H, Castilla C, Ebrahim S, Court R, Nguyen H, Kuritzkes DR, Marconi VC, Nachega JB. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr. 2012;61(2):158–63.